Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. - Wikidata - awgldk - TriplyDB

Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats.

Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats.

http://www.wikidata.org/entity/Q46568195

about

Duchenne Muscular Dystrophy: From Diagnosis to Therapy Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease Micro and nanoparticle drug delivery systems for preventing allotransplant rejection Polymeric nanoparticle technologies for oral drug delivery.Development of a nanoparticulate formulation of retinoic acid that suppresses Th17 cells and upregulates regulatory T cells Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse.Development of a pH-responsive particulate drug delivery vehicle for localized biologic therapy in inflammatory bowel disease Enhanced therapeutic efficacy of budesonide in experimental colitis with enzyme/pH dual-sensitive polymeric nanoparticles Transport of nanocarriers across gastrointestinal epithelial cells by a new transcellular route induced by targeting ICAM-1.Evaluation of anti-inflammatory effect of anti-platelet agent-clopidogrel in experimentally induced inflammatory bowel disease.Nanomedicines for Endothelial Disorders.Polymeric nanoparticle drug delivery technologies for oral delivery applications.Therapeutic effects of Clostridium butyricum on experimental colitis induced by oxazolone in rats Micro/nanostructured polymeric systems for biomedical and pharmaceutical applications.Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells.Intestinal anti-inflammatory effects of RGD-functionalized silk fibroin nanoparticles in trinitrobenzenesulfonic acid-induced experimental colitis in rats.Responses of human cells to ZnO nanoparticles: a gene transcription study.Colonic treatments and targets: issues and opportunities.Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases.Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease.New targeting strategies in drug therapy of inflammatory bowel disease: mechanistic approaches and opportunities.A platelet-inspired paradigm for nanomedicine targeted to multiple diseases.Blockade of CXCR2 signalling: a potential therapeutic target for preventing neutrophil-mediated inflammatory diseases.Nanotechnology in the treatment of inflammatory bowel diseases.Nanomedicines in gastroenterology and hepatology.Size-dependent nanoparticulate drug delivery in inflammatory bowel diseases.5-ASA-loaded SiO2 nanoparticles-a novel drug delivery system targeting therapy on ulcerative colitis in mice Cationic nanoparticles for delivery of amphotericin B: preparation, characterization and activity in vitro.Triblock polymeric micelles as carriers for anti-inflammatory drug delivery.Polymer-based drug delivery: the quest for local targeting of inflamed intestinal mucosa.Using murine colitis models to analyze probiotics-host interactions.A novel preparation method for 5-aminosalicylic acid loaded Eudragit S100 nanoparticles.Preventive Effect of TU-100 on a Type-2 Model of Colitis in Mice: Possible Involvement of Enhancing Adrenomedullin in Intestinal Epithelial Cells.Application of an amine functionalized biopolymer in the colonic delivery of glycyrrhizin: a design and in vivo efficacy study.Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges Development of a new delivery system consisting in 'drug-in cyclodextrin-in PLGA nanoparticles'.Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases.Nanoparticle-based delivery enhances anti-inflammatory effect of low molecular weight heparin in experimental ulcerative colitis.Intestinal organoids containing poly(lactic-co-glycolic acid) nanoparticles for the treatment of inflammatory bowel diseases.

P2860

Q26784259-7378A046-330B-44E9-9066-D1DCEE06D65A Q26992271-67D7E985-B30C-4322-BC96-27B89E5AADCD Q28073219-FBA42C7F-1CC4-4ACF-A6F4-B14C37CBE6E0 Q28080720-9E5B38EA-066A-47C6-8042-CDDA62CEF96A Q34225096-D1F8DDA6-47D0-41F4-8405-BC23B0679C7B Q34707563-78B4F9F1-A413-4309-BF14-CB88CB987C94 Q34749181-78CD8509-9850-4BE2-9DEF-F61592E316E6 Q35228674-44B20CFE-AFD3-494B-AE07-B4A30681EFFA Q35871764-578D7EE2-5FC4-435F-BBAC-F362B119EFE4 Q36291228-79746BAB-ED79-4200-9905-30A85DD7C9EC Q36470212-959C4CB7-DD37-46CA-823D-435F76C5AEA1 Q36651592-5550500F-06AC-4AE7-A5E5-0DAF883AC759 Q36808308-B8448F42-302C-4734-B349-BBC6C858F1B1 Q37161605-8B0FB5B4-2821-43F7-80B1-81FF96B4773B Q37176404-4FBEA6D5-6A99-4C6C-A094-74ADA6599E42 Q37290683-0AC28394-FCD7-4CC5-89F7-751FB28B9660 Q37413157-442498A5-7C55-46F9-A2D3-4B53E2306143 Q37435441-BE5F1010-7FFD-4D80-BE93-611DC2027134 Q37530912-E2609463-5E80-4F78-9679-931E00B758A9 Q37638947-BAFA825A-70FD-47D3-A2DB-96D1802758C5 Q38049367-B0FA8963-1A20-4FAF-95F6-88F11768E150 Q38110619-2447B0D7-F31B-46C1-8484-99D045BE787F Q38145567-B987CA4C-1EAB-442B-A513-51E3616469CA Q38195671-AAE6A1B8-B537-4B0D-820F-2CB3F021883C Q38200842-93D59366-D2E5-4E0E-BD4F-186FF89DE5FE Q38370747-2EC3F425-DED9-4FB1-9D1B-1BDDA1624314 Q38659150-ADFCF5A0-2A5A-4534-940B-303CE74DE82D Q38718705-93BB0B32-0BA5-4E6C-AA84-D0F9EF9F565C Q38787429-D5FD9425-B8C1-41C7-B486-1825585414C3 Q38925600-67B17871-5374-4C17-987E-25DC5868F2CE Q39170844-79F1AF29-5D42-4E21-A815-48BD1B8731D3 Q40084224-B605EB62-EEC0-45D8-A3DA-076F08F40342 Q41806951-56438127-417B-4268-8D85-BD18B4A1DE3E Q41855658-454232DC-8CCE-4BFC-B121-6C792BCD00F9 Q41988650-3DA85EF6-A439-4E41-B2F3-3C10BDF7AD58 Q42375646-889EE91A-F008-4D3D-AE04-18463C92CD4B Q43180561-D73A18BB-758D-4622-9172-837A97B993F2 Q43202907-1318815E-25E6-4DCF-84FF-301510457EEA Q47212964-120DCA8F-EE21-45CD-9AC2-1A325B79A160 Q47262860-BF68C4AF-93D0-4E67-8D09-5354D28655BC

P2860

Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats.

http://www.wikidata.org/entity/Q46568195

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Nanoparticles enhance therapeu ...... experimental colitis in rats.

@en

Nanoparticles enhance therapeu ...... experimental colitis in rats.

@nl

type

label

Nanoparticles enhance therapeu ...... experimental colitis in rats.

@en

Nanoparticles enhance therapeu ...... experimental colitis in rats.

@nl

prefLabel

Nanoparticles enhance therapeu ...... experimental colitis in rats.

@en

Nanoparticles enhance therapeu ...... experimental colitis in rats.

@nl

P1433

Q46568195-087BBE46-2336-471D-9E77-DE19AD631854

P1476

Q46568195-F0E9B11A-D916-461A-8ED5-DC529D498CD3

P2093

Q46568195-14C3C547-65EC-45DB-B6D0-0A6E755ECC68

Q46568195-867721AA-7C53-487A-851B-6ED36C3FC644

Q46568195-876DDEF2-FEA7-4DB7-8345-F39BA8038165

Q46568195-D9B8A8AA-52EB-48DE-8F29-8608A887190E

P304

Q46568195-AB31F8D1-3CB3-4069-B3BB-92F147510802

P31

Q46568195-0BFDCE85-F6EB-4150-B623-E29E5D5D5400

P356

Q46568195-57A46F27-4E95-4C4D-AF80-FD187C7A3260

P407

Q46568195-9A97BFF1-90D4-48C6-98D1-19A40871472D

P433

Q46568195-B0D2EB4C-6019-4084-84A7-86D10C9219A7

P478

Q46568195-9036E4D2-A6C8-4C44-97C0-109017F2F89A

P577

Q46568195-D92CA699-EA08-4556-B79E-94A3EF6D0C59

P5875

Q46568195-795849D2-9BD4-4D98-96F5-4B7B1AFF20F1

P698

Q46568195-D135F7ED-0C45-4927-AC36-15D1FCFAF8DA

P921

Q46568195-F260AC5C-E9A5-4ACC-8096-2D1550032E2A

P356

JPET.105.088146

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

Nanoparticles enhance therapeu ...... experimental colitis in rats.

@en

P2093

Alf Lamprecht

http://www.w3.org/2001/XMLSchema#string

Hirofumi Takeuchi

http://www.w3.org/2001/XMLSchema#string

Hiromitsu Yamamoto

http://www.w3.org/2001/XMLSchema#string

Yoshiaki Kawashima

http://www.w3.org/2001/XMLSchema#string

P304

196-202

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.105.088146

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

315

http://www.w3.org/2001/XMLSchema#string

P577

2005-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7763859

http://www.w3.org/2001/XMLSchema#string

P698

15980057

http://www.w3.org/2001/XMLSchema#string

P921